Advertisement
Screener

Tempest Therapeutics, Inc. (TPST) Deferred Offering Costs

2.8 / 5 stars · 68/120 Roast Me

Tempest Therapeutics, Inc. Deferred Offering Costs

Tempest Therapeutics, Inc. (TPST) had Deferred Offering Costs of $200.00 thousand as of 2019-09-30, per its 10-Q filed 2019-11-13.

Discontinued › Balance Sheet › Assets › Assets, Current

us-gaap:DeferredOfferingCosts · last filed 2019-11-13

  • 2019-09-30: Deferred Offering Costs $200.00K.
  • 2019-06-30: Deferred Offering Costs $200.00K.
  • 2014-12-31: Deferred Offering Costs $100.00K.
Period endDeferred Offering Costs
2019-09-30$200.00K
10-Q · filed 2019-11-13
2019-06-30$200.00K
10-Q · filed 2019-08-12
2014-12-31$100.00K
10-K · filed 2015-03-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
BIOVIE INC. (BIVI)United States$0.012B
MUSTANG BIO, INC. (MBIO)United States$0.013B
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B